All Pharma articles – Page 17
-
Supplements
Value in Healthcare Awards: Workforce Efficiency
Value in Healthcare Awards winners for 2015
-
SupplementsValue in Healthcare Awards 2015
Learn about this year’s winning projects in HSJ’s celebration of organisations delivering real value
-
NewsRevealed: Winners of the Value in Healthcare Awards 2015
Chosen from a record breaking number of entries
-
CommentCuts in cancer spending expose a funding challenge
There will be tough choices over cash and cancer
-
NewsHigh profile treatments cut from cancer drugs fund
High profile cancer treatments including Roche’s Kadcyla and Avastin are to be removed from the cancer drugs fund.
-
CommentKelsey: Urgent action on a digital NHS is a moral imperative
The online revolution hasn’t reached the NHS
-
CommentDrugs access: Why the NHS is failing those with rare conditions
Access to treatment decision making
-
NewsDrug pricing deal change 'cuts NHS England's ability to provide care'
NHS England faces a ‘direct cut’ in its ability to provide care to patients as a result of a change to the deal that caps the price the government pays for branded medicines, a senior health economist has said.
-
NewsNHS staff to face new sanctions under ‘Sunshine rule’
NHS staff who fail to disclose payments and hospitality received from drug suppliers and medical device makers will be sanctioned under new regulation, health secretary Jeremy Hunt has said.
-
NewsBacklash expected over cancer drugs delisting
Talks are under way to identify high profile treatments to be removed from the cancer drugs fund in the coming months, HSJ has learned.
-
-
-
NewsCCG Barometer: explore the data
Findings from HSJ’s summer 2015 CCG barometer, carried out with Capsticks, which focus on commissioners’ approach to financial problems, and preferred solutions for unsustainable providers.
-
NewsDrug pricing scheme ‘must be more transparent’, says commissioning chief
The deal struck between the government and the pharmaceutical industry to limit the amount the NHS spends on branded drugs must become ‘more transparent’, the director of NHS Clinical Commissioners has said.
-
NewsExclusive: Prime minister intervened in NHS England drug decisions
The prime minister intervened in NHS England’s consideration of funding for drugs to treat several rare conditions with a letter to its chief executive, HSJ has learned.
-
HSJ LocalHeart of England to ‘boost efficiency’ by pooling patient data
PERFORMANCE: One of the country’s largest acute trusts is to embark on a research project collecting patient data to improve health outcomes across its patch, HSJ has learned.
-
HSJ LocalUpdated: Manchester plans new NICE relationship and ‘Sunshine Act’
COMMISSIONING: Ambitious proposals have been drawn up which could transform the way medicines and pharmacy services are commissioned in Greater Manchester.
-
NewsNICE approves hep C drugs despite funding concerns
The National Institute for Health and Care Excellence has recommended the use of three new hepatitis C treatments, describing NHS England’s concerns over their cost as ‘not robust’.
-
NewsHigh Court rules against regulator in pharma transparency case
A High Court judge has concluded that the Health Research Authority acted unlawfully in applying new transparency rules on pharmaceutical companies carrying out clinical trials.
-
NewsNHS England director: 'Budget constraint' to blame for hepatitis C drug delays
Delays to the introduction of groundbreaking, cost effective hepatitis C drugs have occurred because of ‘budget constraint’, NHS England’s specialised commissioning director has indicated.